Improvement of cardiac performance by pimobendan, a new cardiotonic drug, in the experimental failing dog heart.
The cardiotonic effect of pimobendan was studied in 6 dog heart-lung preparations in which cardiac function had been severely depressed by pentobarbital. Pimobendan in doses of 1-10 mg improved cardiac function in a dose-dependent manner and at 10 mg improved it beyond the control. These doses of pimobendan, however, produced neither a significant increase in heart rate nor arrhythmias. The results indicate that the drug may be of use in the treatment of heart failure.
Satoh
K
K
Department of Pharmacology, Tohoku University School of Medicine, Sendai, Japan.
Satoh
Y
Y
Imagawa
J
J
Taira
N
N
D000818:Animals; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D006321:Heart / Q000187:drug effects*; D006333:Heart Failure / Q000188:drug therapy*; D008297:Male; D010477:Perfusion; D011724:Pyridazines / Q000627:therapeutic use*
D002316:Cardiotonic Agents; D011724:Pyridazines; C041648:pimobendan